Radiobiology 2016

Hyperfractionation in NSCLC RTOG 83-11/ ECOG 4588, Phase III, NSCLC II-IIIB

Survival

Schedule

n

MST

1yr

2yrs

4yrs

60.0 Gy/ 2.0 Gy

152

11.4 m

46%

20%

4%

69.6 Gy/ 1.2 Gy b.i.d.

154

12.3 m

51%

24%

9%

n.s. Third arm neoadj. ChT

Sause et al., J. Natl. Cancer Inst. 87: 198-205, 1995 Komaki et al., IJROBP 39: 537-544, 1997

ESTRO